Adrian Koh Selected Research

Photochemotherapy (Photodynamic Therapy)

1/2020	Comparison of Ranibizumab With or Without Verteporfin Photodynamic Therapy for Polypoidal Choroidal Vasculopathy: The EVEREST II Randomized Clinical Trial.
11/2017	Efficacy and Safety of Ranibizumab With or Without Verteporfin Photodynamic Therapy for Polypoidal Choroidal Vasculopathy: A Randomized Clinical Trial.
9/2012	EVEREST study: efficacy and safety of verteporfin photodynamic therapy in combination with ranibizumab or alone versus ranibizumab monotherapy in patients with symptomatic macular polypoidal choroidal vasculopathy.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Adrian Koh Research Topics

Disease

9	Macular Degeneration (Age-Related Maculopathy) 01/2022 - 05/2017
8	Polypoidal Choroidal Vasculopathy 01/2022 - 09/2012
4	Diabetic Retinopathy (Retinopathy, Diabetic) 01/2022 - 01/2021
3	Atrophy 06/2023 - 12/2009
3	Polyps 01/2022 - 09/2012
3	COVID-19 03/2021 - 06/2020
2	Retinal Vein Occlusion 01/2022 - 01/2022
2	Vascular Diseases (Vascular Disease) 01/2022 - 01/2022
2	Retinal Diseases 03/2021 - 06/2020
2	Macular Edema 11/2019 - 07/2015
2	Vision Disorders (Hemeralopia) 05/2017 - 07/2015
2	Hemorrhage 07/2015 - 11/2004
1	Edema (Dropsy) 01/2023
1	Choroidal Neovascularization 01/2022
1	Inflammation (Inflammations) 01/2022
1	Infections 03/2021
1	Cicatrix (Scar) 01/2021
1	Glaucoma 09/2020
1	Cataract (Cataracts) 09/2020
1	Blindness (Hysterical Blindness) 05/2017
1	Ischemia 07/2015
1	Dengue (Dengue Fever) 11/2004
1	Retinal Degeneration 07/2004
1	Myopia 03/2002

Drug/Important Bio-Agent (IBA)

7	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 06/2023 - 05/2017
7	afliberceptIBA 01/2022 - 05/2017
6	Retinaldehyde (Retinal)IBA 06/2023 - 11/2004
6	brolucizumabIBA 01/2022 - 01/2020
6	Ranibizumab (Lucentis)FDA Link 08/2020 - 09/2012
3	Verteporfin (Visudyne)FDA Link 01/2020 - 09/2012
2	1-phenyl-3,3-dimethyltriazene (PDT)IBA 01/2022 - 09/2012
2	SteroidsIBA 09/2020 - 11/2019
2	Mydriatics (Cycloplegics)IBA 07/2004 - 03/2002
1	Biomarkers (Surrogate Marker)IBA 01/2022
1	salicylhydroxamic acid (SHAM)IBA 01/2022
1	Immunoglobulin FragmentsIBA 01/2020
1	Dexamethasone (Maxidex)FDA LinkGeneric 10/2016
1	Indocyanine Green (Cardio-Green)FDA LinkGeneric 09/2012
1	Retinal Pigments (Pigments, Visual)IBA 12/2009
1	AntibodiesIBA 11/2004
1	Immunoglobulin M (IgM)IBA 11/2004
1	EnzymesIBA 11/2004
1	Ophthalmic Solutions (Eye Drops)IBA 03/2002
1	Atropine FDA LinkGeneric 03/2002

Therapy/Procedure

6	Therapeutics 01/2023 - 05/2017
4	Injections 01/2022 - 10/2016
3	Photochemotherapy (Photodynamic Therapy) 01/2020 - 09/2012
2	Intravitreal Injections 03/2021 - 06/2020
2	Lasers (Laser) 11/2019 - 07/2015
1	Personal Protective Equipment 03/2021
1	Treatment Delay 01/2021
1	Light Coagulation 11/2019
1	Hydrophilic Contact Lenses (Hydrophilic Contact Lens) 03/2002
1	Contact Lenses 03/2002
1	Lenses 03/2002